<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
<journal-id journal-id-type="publisher-id">CAM4</journal-id>
<journal-title-group>
<journal-title>Cancer Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2045-7634</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31856408</article-id>
<article-id pub-id-type="pmc">6997076</article-id>
<article-id pub-id-type="doi">10.1002/cam4.2692</article-id>
<article-id pub-id-type="publisher-id">CAM42692</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Cancer Prevention</subject>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Bioinformatic profiling identifies a platinum‐resistant–related risk signature for ovarian cancer</article-title>
<alt-title alt-title-type="left-running-head">WU et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="cam42692-cr-0001">
<name>
<surname>Wu</surname>
<given-names>Ce</given-names>
</name>
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-3791-5912</contrib-id>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam42692-cr-0002">
<name>
<surname>He</surname>
<given-names>Linxiu</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam42692-cr-0003">
<name>
<surname>Wei</surname>
<given-names>Qian</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam42692-cr-0004">
<name>
<surname>Li</surname>
<given-names>Qian</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam42692-cr-0005">
<name>
<surname>Jiang</surname>
<given-names>Longyang</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam42692-cr-0006">
<name>
<surname>Zhao</surname>
<given-names>Lan</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="cam42692-cr-0007">
<name>
<surname>Wang</surname>
<given-names>Chunyan</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0003">
<sup>3</sup>
</xref>
<address>
<email>lwwcytt@sina.com</email>
</address>
</contrib>
<contrib contrib-type="author" corresp="yes" id="cam42692-cr-0008">
<name>
<surname>Li</surname>
<given-names>Jianping</given-names>
</name>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0004">
<sup>4</sup>
</xref>
<address>
<email>ljp_63@163.com</email>
</address>
</contrib>
<contrib contrib-type="author" corresp="yes" id="cam42692-cr-0009">
<name>
<surname>Wei</surname>
<given-names>Minjie</given-names>
</name>
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-0404-7098</contrib-id>
<xref ref-type="aff" rid="cam42692-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cam42692-aff-0002">
<sup>2</sup>
</xref>
<address>
<email>weiminjiecmu@163.com</email>
</address>
</contrib>
</contrib-group>
<aff id="cam42692-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Pharmacology</named-content>
<named-content content-type="organisation-division">School of Pharmacy</named-content>
<institution>China Medical University</institution>
<city>Shenyang City</city>
<country country="CN">China</country>
</aff>
<aff id="cam42692-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Liaoning Key Laboratory of Molecular Targeted Anti‐Tumor Drug Development and Evaluation</named-content>
<institution>China Medical University</institution>
<city>Shenyang City</city>
<country country="CN">China</country>
</aff>
<aff id="cam42692-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Liaoning Cancer Hospital and Institute</named-content>
<institution>Cancer Hospital of China Medical University</institution>
<city>Shenyang City</city>
<country country="CN">China</country>
</aff>
<aff id="cam42692-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Liaoning Blood Center</named-content>
<institution>Liaoning Provincial Key Laboratory for Blood Safety Research</institution>
<city>Shenyang</city>
<country country="CN">China</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Chunyan Wang, The 4th Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang City, 110042, Liaoning, China.<break></break>
Email: <email>lwwcytt@sina.com</email><break></break>
Jianping Li, Liaoning Blood Center, 13 Beihai Street, Dadong District, Shenyang, 110044, Liaoning, China.<break></break>
Email: <email>ljp_63@163.com</email><break></break>
and<break></break>
Minjie Wei, Department of Pharmacology, School of Pharmacy, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang City, 110122, Liaoning, China.<break></break>
Email: <email>weiminjiecmu@163.com</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2020</year>
</pub-date>
<volume>9</volume>
<issue>3</issue>
<issue-id pub-id-type="doi">10.1002/cam4.v9.3</issue-id>
<fpage>1242</fpage>
<lpage>1253</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>17</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Published by John Wiley & Sons Ltd. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:CAM4-9-1242.pdf"></self-uri>
<abstract id="cam42692-abs-0001">
<title>Abstract</title>
<p>Most high‐grade serous ovarian cancer (HGSOC) patients develop resistance to platinum‐based chemotherapy and recur. Many biomarkers related to the survival and prognosis of drug‐resistant patients have been delved by mining databases; however, the prediction effect of single‐gene biomarker is not specific and sensitive enough. The present study aimed to develop a novel prognostic gene signature of platinum‐based resistance for patients with HGSOC. The gene expression profiles were obtained from Gene Expression Omnibus and The Cancer Genome Atlas database. A total of 269 differentially expressed genes (DEGs) associated with platinum resistance were identified (<italic>P </italic>&lt; .05, fold change &gt;1.5). Functional analysis revealed that these DEGs were mainly involved in apoptosis process, PI3K‐Akt pathway. Furthermore, we established a set of seven‐gene signature that was significantly associated with overall survival (OS) in the test series. Compared with the low‐risk score group, patients with a high‐risk score suffered poorer OS (<italic>P</italic> &lt; .001). The area under the curve (AUC) was found to be 0.710, which means the risk score had a certain accuracy on predicting OS in HGSOC (AUC &gt; 0.7). Surprisingly, the risk score was identified as an independent prognostic indicator for HGSOC (<italic>P</italic> &lt; .001). Subgroup analyses suggested that the risk score had a greater prognostic value for patients with grade 3‐4, stage III‐IV, venous invasion and objective response. In conclusion, we developed a seven‐gene signature relating to platinum resistance, which can predict survival for HGSOC and provide novel insights into understanding of platinum resistance mechanisms and identification of HGSOC patients with poor prognosis.</p>
</abstract>
<abstract abstract-type="graphical" id="cam42692-abs-0002">
<p>The present study aimed to develop a novel prognostic gene signature of platinum‐based resistance for patients with HGSOC. We developed a seven‐gene signature relating to platinum‐resistance, which can predict survival for HGSOC and provide novel insights into understanding of platinum‐resistance mechanisms and identification of HGSOC patients with poor prognosis.<boxed-text content-type="graphic" id="cam42692-blkfxd-0001" orientation="portrait" position="anchor"><graphic id="nlm-graphic-1" orientation="portrait" position="anchor" xlink:href="CAM4-9-1242-g006.jpg"></graphic></boxed-text>
</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="cam42692-kwd-0001">bioinformatics</kwd>
<kwd id="cam42692-kwd-0002">high‐grade serous ovarian cancer</kwd>
<kwd id="cam42692-kwd-0003">platinum resistance</kwd>
<kwd id="cam42692-kwd-0004">prognosis</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-0001">
<funding-source>
<institution-wrap>
<institution>National Natural Science Foundation of China </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100001809</institution-id>
</institution-wrap>
</funding-source>
<award-id>81573462</award-id>
</award-group>
<award-group id="funding-0002">
<funding-source>Liaoning Province Scientific Research Foundation</funding-source>
<award-id>20170541024</award-id>
</award-group>
<award-group id="funding-0003">
<funding-source>Shenyang S&amp;T Projects</funding-source>
<award-id>Z18‐4‐020</award-id>
</award-group>
<award-group id="funding-0004">
<funding-source>National Natural Science Foundation of China and Liaoning joint fund key program</funding-source>
<award-id>U1608281</award-id>
</award-group>
<award-group id="funding-0005">
<funding-source>The Key Laboratory Foundation from Shenyang S&amp;T Projects</funding-source>
<award-id>F16‐094‐1‐00</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="5"></table-count>
<page-count count="12"></page-count>
<word-count count="6460"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>February 2020</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.5 mode:remove_FC converted:03.02.2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="cam42692-cit-1001" publication-type="journal">
<string-name>
<surname>Wu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Bioinformatic profiling identifies a platinum‐resistant–related risk signature for ovarian cancer</article-title>. <source xml:lang="en"/>Cancer Med. <year>2020</year>;<volume>9</volume>:<fpage>1242</fpage>–<lpage>1253</lpage>. <pub-id pub-id-type="doi">10.1002/cam4.2692</pub-id>
</mixed-citation>
</p>
</notes>
</front>
<body id="cam42692-body-0001">
<sec id="cam42692-sec-0001">
<label>1</label>
<title>INTRODUCTION</title>
<p>Ovarian cancer is the most lethal gynecological malignancy in the world. It accounts for 2.5% of female malignant tumors, but 5% of cancer deaths due to low survival rates.<xref ref-type="ref" rid="cam42692-bib-0001">1</xref> There are four main histotypes of ovarian cancer: serous, endometrioid, mucinous, and clear cell.<xref ref-type="ref" rid="cam42692-bib-0002">2</xref> High‐grade serous ovarian cancer (HGSOC) has been thought to be the first leading histological subtype of ovarian cancer death. It is characterized by advanced stage at diagnosis and rapid progress.<xref ref-type="ref" rid="cam42692-bib-0003">3</xref> Combination chemotherapy with platinum compounds and taxanes for six cycles after cytoreductive surgery is a standard adjuvant treatment for patients with ovarian cancer. The majority of HGSOC patients responds well to platinum‐based chemotherapy. And 5‐year survival rates for ovarian cancer have largely improved from 40% to 47% over the last decades.<xref ref-type="ref" rid="cam42692-bib-0001">1</xref> Despite high validity of standard treatment, many patients suffer platinum resistance after initial response, which is one of the causes for low survival rate in HGSOC. Therefore, studying prognostic signatures will be pivotal to improve clinical treatment of HGSOC patients.</p>
<p>Currently, several biomarkers have been used to predict patients’ survival in HGSOC. For example, it has been well established that carbohydrate antigen 125 (CA125) is a dominant feature in diagnosis of ovarian cancer clinically.<xref ref-type="ref" rid="cam42692-bib-0004">4</xref> CA125 has provided useful information on identifying patients for secondary tumor‐debulking surgery, as well as treatment time for multiple conventional and novel drugs.<xref ref-type="ref" rid="cam42692-bib-0002">2</xref> Unfortunately, some studies have failed to define CA125 levels as an independent factor of prognosis or a target to improve overall survival (OS) of patients.<xref ref-type="ref" rid="cam42692-bib-0005">5</xref>, <xref ref-type="ref" rid="cam42692-bib-0006">6</xref>, <xref ref-type="ref" rid="cam42692-bib-0007">7</xref> Bioinformatics is fast becoming a key tool in helping investigators with new research ideas about cancer. Although there is a growing body of literature that recognizes the effect of mRNA expression signatures on recurrence<xref ref-type="ref" rid="cam42692-bib-0008">8</xref>, <xref ref-type="ref" rid="cam42692-bib-0009">9</xref> or OS,<xref ref-type="ref" rid="cam42692-bib-0008">8</xref>, <xref ref-type="ref" rid="cam42692-bib-0010">10</xref>, <xref ref-type="ref" rid="cam42692-bib-0011">11</xref>, <xref ref-type="ref" rid="cam42692-bib-0012">12</xref> there are few integrated analysis have studied the association between gene expression related to platinum resistance and OS of HGSOC.</p>
<p>In this study, the Gene Expression Omnibus (GEO) database<xref ref-type="ref" rid="cam42692-bib-0013">13</xref> was used to obtain differentially expression genes between platinum‐sensitive and resistant HGSOC tissue samples. The Cancer Genome Atlas (TCGA) database<xref ref-type="ref" rid="cam42692-bib-0014">14</xref> was used to identify a model consisted of mRNAs as a new indicator to predict outcome by analyzing the mRNA expression profiles and clinical features in HGSOC. Furthermore, the prognostic value of the indicator was also confirmed in patients with different clinical characteristics.</p>
</sec>
<sec id="cam42692-sec-0002" sec-type="materials-and-methods">
<label>2</label>
<title>MATERIALS AND METHODS</title>
<sec id="cam42692-sec-0003">
<label>2.1</label>
<title>Datasets and patients’ information</title>
<p>Four datasets (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51373">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51373</ext-link>,<xref ref-type="ref" rid="cam42692-bib-0015">15</xref>
<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32602">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32602</ext-link>,<xref ref-type="ref" rid="cam42692-bib-0016">16</xref>
<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65986">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65986</ext-link>,<xref ref-type="ref" rid="cam42692-bib-0017">17</xref>
<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26193">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26193</ext-link>
<xref ref-type="ref" rid="cam42692-bib-0018">18</xref>) with tissue, histological type, histological grade, progression free survival (PFS), and drugs information were included for the analysis differentially expressed genes (DEGs) between platinum‐sensitive and resistant samples in HGSOC. Platform used in these datasets was GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array). Platinum‐resistant disease was characterized by PFS of &lt;6 months after the last platinum‐based treatment. Patients with PFS of &gt;12 months had platinum‐sensitive disease.<xref ref-type="ref" rid="cam42692-bib-0002">2</xref> Overall, 104 HGSOC patients were selected for the analysis including data from 87 platinum‐sensitive samples and 17 platinum‐resistant samples (Table <xref ref-type="table" rid="cam42692-tbl-0001">1</xref>). The expression data and clinical data were downloaded from GEO Databases (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>). To test the prognostic significance of DEGs, gene expression data (level 3) of HGSOC patients from TCGA Databases (<ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>) with available clinical data were used.</p>
<table-wrap id="cam42692-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Top 10 up‐regulated differentially expressed genes (sorted by Fc)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">mRNA</th>
<th align="left" colspan="1" rowspan="1" valign="top">Official full name</th>
<th align="left" colspan="1" rowspan="1" valign="top">Fc</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<italic>P</italic>‐value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">C2orf40</td>
<td align="left" colspan="1" rowspan="1">Chromosome 2 Open Reading Frame 40</td>
<td align="char" char="." colspan="1" rowspan="1">1.62</td>
<td align="char" char="." colspan="1" rowspan="1">.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FAM84A</td>
<td align="left" colspan="1" rowspan="1">Family with Sequence Similarity 84, Member A</td>
<td align="char" char="." colspan="1" rowspan="1">1.51</td>
<td align="char" char="." colspan="1" rowspan="1">.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NLGN4X</td>
<td align="left" colspan="1" rowspan="1">Neuroligin 4, X‐linked</td>
<td align="char" char="." colspan="1" rowspan="1">1.32</td>
<td align="char" char="." colspan="1" rowspan="1">.004</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CMBL</td>
<td align="left" colspan="1" rowspan="1">Carboxymethylenebutenolidase Homolog (Pseudomonas)</td>
<td align="char" char="." colspan="1" rowspan="1">1.19</td>
<td align="char" char="." colspan="1" rowspan="1">.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CNTN3</td>
<td align="left" colspan="1" rowspan="1">Contactin 3 (plasmacytoma associated)</td>
<td align="char" char="." colspan="1" rowspan="1">1.18</td>
<td align="char" char="." colspan="1" rowspan="1">.006</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MUM1L1</td>
<td align="left" colspan="1" rowspan="1">Melanoma Associated Antigen (mutated) 1‐like 1</td>
<td align="char" char="." colspan="1" rowspan="1">1.18</td>
<td align="char" char="." colspan="1" rowspan="1">.012</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PCP4</td>
<td align="left" colspan="1" rowspan="1">Purkinje Cell Protein 4</td>
<td align="char" char="." colspan="1" rowspan="1">1.17</td>
<td align="char" char="." colspan="1" rowspan="1">.020</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SOX11</td>
<td align="left" colspan="1" rowspan="1">SRY (sex determining region Y)‐box 11</td>
<td align="char" char="." colspan="1" rowspan="1">1.10</td>
<td align="char" char="." colspan="1" rowspan="1">.033</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TCEAL2</td>
<td align="left" colspan="1" rowspan="1">Transcription Elongation Factor A (SII)‐like 2</td>
<td align="char" char="." colspan="1" rowspan="1">1.09</td>
<td align="char" char="." colspan="1" rowspan="1">.019</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PCSK1N</td>
<td align="left" colspan="1" rowspan="1">Proprotein Convertase Subtilisin/kexin Type 1 Inhibitor</td>
<td align="char" char="." colspan="1" rowspan="1">1.07</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="cam42692-sec-0004">
<label>2.2</label>
<title>Identification of DEGs in HGSOC samples</title>
<p>Linear models for microarray data (limma) package<xref ref-type="ref" rid="cam42692-bib-0019">19</xref> were used for differential expression analysis. Robust multichip average (RMA) method was used for data normalization. Imputation for microarray data (impute) package<xref ref-type="ref" rid="cam42692-bib-0020">20</xref> was used to impute missing expression data. Surrogate variable analysis package<xref ref-type="ref" rid="cam42692-bib-0021">21</xref> was used for removing batch effects and other unwanted variations in experiment. Expression difference was characterized by fold change (Fc) and <italic>P</italic>‐valve. Fc was defined by the ratio between platinum‐resistant group and sensitive group in expression value of each gene. Genes with Fc＞1.5 and <italic>P</italic> &lt; .05 were defined as DEGs.</p>
</sec>
<sec id="cam42692-sec-0005">
<label>2.3</label>
<title>Gene annotation and pathway enrichment analyses</title>
<p>The Database for Annotation, Visualization and Integrated Discovery (DAVID, <ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/home.jsp">https://david.ncifcrf.gov/home.jsp</ext-link>)<xref ref-type="ref" rid="cam42692-bib-0022">22</xref> was used to perform gene function annotation and pathway enrichment analysis. Gene annotations were performed from three aspects, namely, cellular component, biological process, and molecular function by gene ontology. KEGG (Kyoto Encyclopedia of Genes and Genomes)<xref ref-type="ref" rid="cam42692-bib-0023">23</xref> pathway enrichment analyses were also performed to investigate the underlying functions of aforementioned DEGs. <italic>P</italic> &lt; .05 was used as the significance level.</p>
</sec>
<sec id="cam42692-sec-0006">
<label>2.4</label>
<title>Construction of the DEGs‐based prognostic model and data analysis</title>
<p>Package survival<xref ref-type="ref" rid="cam42692-bib-0024">24</xref>was used for Cox proportional hazard regression to construct the prognostic model. The univariate regression with <italic>P </italic>&lt; .05 was used to identify OS related mRNAs from the DEGs. The multivariate regression was used to confirm mRNAs selected by that univariate regression could be brought into prognostic model and calculate risk score. The risk score of each patient was calculated according to the formula: risk score = <italic>h</italic>0 (<italic>t</italic>) exp (<italic>β</italic>1*<italic>X</italic>1 + <italic>β</italic>1*<italic>X</italic>1 + … <italic>βn</italic>*<italic>Xn</italic>) (<italic>X</italic>: gene expression value; <italic>β</italic>: the coefficient derived from multivariate regression; <italic>h</italic> (0): baseline hazard function, not specified). HGSOC patients were divided into high‐risk group and low‐risk group according to the median risk score.<xref ref-type="ref" rid="cam42692-bib-0025">25</xref> Survival curves were created using survfit functions. And survdiff function was used to test survival curve differences. Package survival receiver operating characteristic (ROC)<xref ref-type="ref" rid="cam42692-bib-0026">26</xref> was used to create ROC curve to assess the predictive accuracy of the risk score for time‐dependent disease outcomes within 3 years. Cox regression was also performed to evaluate the effect and independence of risk score and clinicopathological parameters, including age, histological grade, stage, residual tumor size, anatomic neoplasm subdivision, and treatment outcome on OS of HGSOC patients.</p>
</sec>
</sec>
<sec id="cam42692-sec-0007" sec-type="results">
<label>3</label>
<title>RESULTS</title>
<sec id="cam42692-sec-0008">
<label>3.1</label>
<title>Identification of DEGs involved in platinum‐resistant HGSOC and pathway enrichment analyses</title>
<p>The gene expression profile with accession numbers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51373">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51373</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32062">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32062</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65986">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65986</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26193">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26193</ext-link> were downloaded from GEO database. The volcano plot (Figure <xref ref-type="supplementary-material" rid="cam42692-sup-0001">S1</xref>A) showed the difference of mRNA expression between platinum‐sensitive (n = 87) and resistant group (n = 17). Compared with the sensitive group, 269 DEGs were obtained including 123 up‐regulated and 146 down‐regulated in the resistant group (<italic>P</italic> &lt; .05, Fc &gt; 1.5). The heatmap presented the expression of DEGs with <italic>P</italic> &lt; .05 and Fc &gt; 1.5 (Figure <xref ref-type="supplementary-material" rid="cam42692-sup-0001">S1</xref>B). The top 10 up‐regulated and down‐regulated DEGs (sorted by Fc) are displayed in Tables <xref ref-type="table" rid="cam42692-tbl-0001">1</xref> and <xref ref-type="table" rid="cam42692-tbl-0002">2</xref>. Then we performed gene function analysis through the web‐tool: DAVID. As shown in Figure <xref ref-type="fig" rid="cam42692-fig-0001">1</xref>, DEGs were significantly enriched in cellular components (Figure <xref ref-type="fig" rid="cam42692-fig-0001">1</xref>A), protein homodimerization activity (Figure <xref ref-type="fig" rid="cam42692-fig-0001">1</xref>B), signal transduction, immune response, and apoptotic process (Figure <xref ref-type="fig" rid="cam42692-fig-0001">1</xref>C). And KEGG analysis (Figure <xref ref-type="fig" rid="cam42692-fig-0001">1</xref>D) showed that DEGs were enriched in the PI3K‐Akt signaling pathway, drug metabolism‐cytochrome P450, etc, <italic>P</italic> &lt; .05 was used as the significance level.</p>
<table-wrap id="cam42692-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Top 10 down‐regulated differentially expressed genes (sorted by Fc)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">mRNA</th>
<th align="left" colspan="1" rowspan="1" valign="top">Official full name</th>
<th align="left" colspan="2" rowspan="1" valign="top">Fc</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<italic>P</italic>‐value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">IGLC1</td>
<td align="left" colspan="2" rowspan="1">Immunoglobulin Lambda Constant 1 (Mcg marker)</td>
<td align="char" char="." colspan="1" rowspan="1">2.21</td>
<td align="char" char="." colspan="1" rowspan="1">.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL10</td>
<td align="left" colspan="2" rowspan="1">Chemokine (C‐X‐C motif) Ligand 10</td>
<td align="char" char="." colspan="1" rowspan="1">1.51</td>
<td align="char" char="." colspan="1" rowspan="1">.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL11</td>
<td align="left" colspan="2" rowspan="1">Chemokine (C‐X‐C motif) Ligand 11</td>
<td align="char" char="." colspan="1" rowspan="1">1.49</td>
<td align="char" char="." colspan="1" rowspan="1">.007</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HLA‐DRB4</td>
<td align="left" colspan="2" rowspan="1">Major Histocompatibility Complex, Class II, DR beta 4</td>
<td align="char" char="." colspan="1" rowspan="1">1.25</td>
<td align="char" char="." colspan="1" rowspan="1">.038</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL9</td>
<td align="left" colspan="2" rowspan="1">Chemokine (C‐X‐C motif) Ligand 9</td>
<td align="char" char="." colspan="1" rowspan="1">1.23</td>
<td align="char" char="." colspan="1" rowspan="1">.016</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL13</td>
<td align="left" colspan="2" rowspan="1">Chemokine (C‐X‐C motif) Ligand 13</td>
<td align="char" char="." colspan="1" rowspan="1">1.17</td>
<td align="char" char="." colspan="1" rowspan="1">.010</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL8</td>
<td align="left" colspan="2" rowspan="1">Chemokine (C‐X‐C motif) Ligand 8</td>
<td align="char" char="." colspan="1" rowspan="1">1.17</td>
<td align="char" char="." colspan="1" rowspan="1">.008</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GBP1</td>
<td align="left" colspan="2" rowspan="1">Guanylate Binding Protein 1, Interferon‐inducible</td>
<td align="char" char="." colspan="1" rowspan="1">1.16</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ADAMDEC1</td>
<td align="left" colspan="2" rowspan="1">ADAM‐like, Decysin 1</td>
<td align="char" char="." colspan="1" rowspan="1">1.14</td>
<td align="char" char="." colspan="1" rowspan="1">.012</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SAMD9</td>
<td align="left" colspan="2" rowspan="1">Sterile Alpha Motif Domain Containing 9</td>
<td align="char" char="." colspan="1" rowspan="1">1.11</td>
<td align="char" char="." colspan="1" rowspan="1">.001</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<fig fig-type="Figure" id="cam42692-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Differentially expressed genes were enriched in (A) cellular component, (B) molecular function, (C) biological process, and (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (more details are presented in Table <xref ref-type="supplementary-material" rid="cam42692-sup-0004">S1</xref>)</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="CAM4-9-1242-g001"></graphic>
</fig>
</sec>
<sec id="cam42692-sec-0009">
<label>3.2</label>
<title>Construction of DEG‐based prognostic model</title>
<p>To explore whether DEGs are related to OS, 333 HGSOC samples with the expression profile in TCGA databases were selected for the Cox regression analysis. Univariate Cox regression showed that 12 of 269 DEGs were determined to be associated with OS in HGSOC significantly (<italic>P</italic> &lt; .05, Table <xref ref-type="table" rid="cam42692-tbl-0003">3</xref>), while multivariate Cox regression indicated that seven DEGs were included in the prognostic model (Table <xref ref-type="table" rid="cam42692-tbl-0003">3</xref>). Among them, LYPD6B, CD38, CMBL, and KIAA2022 were independent protective factors due to hazard ratio (HR) being less than 1. On the contrary, LYRRC17, ZHX3, and AKR1B10 were independent risky factors for OS in HGSOC patients, as the HR were greater than 1.</p>
<table-wrap id="cam42692-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Univariate and Multivariate analysis associated with overall survival in patients with high‐grade serous ovarian cancer</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="bottom">mRNA</th>
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Univariate Cox regression</th>
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Multivariate Cox regression</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>β</italic> (Cox)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>P</italic>
</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">HR (95% CI)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>β</italic> (Cox)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>P</italic>
</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">CD38</td>
<td align="char" char="." colspan="1" rowspan="1">−0.122</td>
<td align="char" char="." colspan="1" rowspan="1">.007</td>
<td align="char" char="(" colspan="1" rowspan="1">0.885 (0.811‐0.967)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.143</td>
<td align="char" char="." colspan="1" rowspan="1">.002</td>
<td align="char" char="(" colspan="1" rowspan="1">0.866 (0.793‐0.947)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FCGBP</td>
<td align="char" char="." colspan="1" rowspan="1">0.110</td>
<td align="char" char="." colspan="1" rowspan="1">.013</td>
<td align="char" char="(" colspan="1" rowspan="1">1.117 (1.023‐1.219)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PDK4</td>
<td align="char" char="." colspan="1" rowspan="1">0.184</td>
<td align="char" char="." colspan="1" rowspan="1">.017</td>
<td align="char" char="(" colspan="1" rowspan="1">1.202 (1.033‐1.398)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL13</td>
<td align="char" char="." colspan="1" rowspan="1">−0.068</td>
<td align="char" char="." colspan="1" rowspan="1">.022</td>
<td align="char" char="(" colspan="1" rowspan="1">0.934 (0.881‐0.990)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ATP1A2</td>
<td align="char" char="." colspan="1" rowspan="1">0.079</td>
<td align="char" char="." colspan="1" rowspan="1">.024</td>
<td align="char" char="(" colspan="1" rowspan="1">1.082 (1.010‐1.159)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AKR1B10</td>
<td align="char" char="." colspan="1" rowspan="1">0.074</td>
<td align="char" char="." colspan="1" rowspan="1">.032</td>
<td align="char" char="(" colspan="1" rowspan="1">1.077 (1.006‐1.153)</td>
<td align="char" char="." colspan="1" rowspan="1">0.101</td>
<td align="char" char="." colspan="1" rowspan="1">.006</td>
<td align="char" char="(" colspan="1" rowspan="1">1.106 (1.030‐1.187)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LYPD6B</td>
<td align="char" char="." colspan="1" rowspan="1">−0.116</td>
<td align="char" char="." colspan="1" rowspan="1">.033</td>
<td align="char" char="(" colspan="1" rowspan="1">0.890 (0.800‐0.990)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.121</td>
<td align="char" char="." colspan="1" rowspan="1">.031</td>
<td align="char" char="(" colspan="1" rowspan="1">0.886 (0.794‐0.989)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ADAMDEC1</td>
<td align="char" char="." colspan="1" rowspan="1">−0.065</td>
<td align="char" char="." colspan="1" rowspan="1">.033</td>
<td align="char" char="(" colspan="1" rowspan="1">0.937 (0.882‐0.995)</td>
<td align="char" char="." colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="char" char="." colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LRRC17</td>
<td align="char" char="." colspan="1" rowspan="1">0.108</td>
<td align="char" char="." colspan="1" rowspan="1">.037</td>
<td align="char" char="(" colspan="1" rowspan="1">1.115 (1.007‐1.234)</td>
<td align="char" char="." colspan="1" rowspan="1">0.170</td>
<td align="char" char="." colspan="1" rowspan="1">.005</td>
<td align="char" char="(" colspan="1" rowspan="1">1.185 (1.052‐1.336)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CMBL</td>
<td align="char" char="." colspan="1" rowspan="1">−0.104</td>
<td align="char" char="." colspan="1" rowspan="1">.041</td>
<td align="char" char="(" colspan="1" rowspan="1">0.901 (0.815‐0.996)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.159</td>
<td align="char" char="." colspan="1" rowspan="1">.003</td>
<td align="char" char="(" colspan="1" rowspan="1">0.853 (0.768‐0.948)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ZHX3</td>
<td align="char" char="." colspan="1" rowspan="1">0.206</td>
<td align="char" char="." colspan="1" rowspan="1">.043</td>
<td align="char" char="(" colspan="1" rowspan="1">1.229 (1.007‐1.499)</td>
<td align="char" char="." colspan="1" rowspan="1">0.235</td>
<td align="char" char="." colspan="1" rowspan="1">.041</td>
<td align="char" char="(" colspan="1" rowspan="1">1.265 (1.010‐1.584)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">KIAA2022</td>
<td align="char" char="." colspan="1" rowspan="1">−0.076</td>
<td align="char" char="." colspan="1" rowspan="1">.045</td>
<td align="char" char="(" colspan="1" rowspan="1">0.927 (0.861‐0.998)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.124</td>
<td align="char" char="." colspan="1" rowspan="1">.004</td>
<td align="char" char="(" colspan="1" rowspan="1">0.883 (0.811‐0.962)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="cam42692-sec-0010">
<label>3.3</label>
<title>The risk score as an independent prognosis indicator in HGSOC</title>
<p>Risk scores for each patient were calculated according to the formula mentioned in the materials and methods. All patients were divided into two groups: low‐risk group (n = 167) and high‐risk group (n = 166) by the median value of risk score (Figure <xref ref-type="fig" rid="cam42692-fig-0002">2</xref>A). Patients survival status is shown in Figure <xref ref-type="fig" rid="cam42692-fig-0002">2</xref>B. The different expression patterns of the seven DEGs in the low‐ and high‐risk groups are showed in heatmap (Figure <xref ref-type="fig" rid="cam42692-fig-0002">2</xref>C). As the value of risk score increased, the expression of protection factors tend to decrease, while the risky mRNAs tend to increase in expression. The survival curves revealed patients with high‐risk scores suffered poorer prognosis compared with the low‐risk group (<italic>P</italic> &lt; .001, Figure <xref ref-type="fig" rid="cam42692-fig-0003">3</xref>A). The most striking result to emerge from the data is that the area under ROC curve (AUC) was 0.710 (Figure <xref ref-type="fig" rid="cam42692-fig-0003">3</xref>B), indicating that the risk score had a certain accuracy on predicting 3‐year OS in HGSOC. In addition, to determine whether the prognostic function of the risk score derives from one mRNA, we drew survival curves (Figure <xref ref-type="supplementary-material" rid="cam42692-sup-0002">S2</xref>) and ROC curves (Figure <xref ref-type="supplementary-material" rid="cam42692-sup-0003">S3</xref>) of every single mRNA. It is regrettable that none of these mRNAs was an accurate predictor of OS in HGSOC with AUC for ROC &lt;0.7, which means the prognostic value of risk score was higher than any single mRNA.</p>
<fig fig-type="Figure" id="cam42692-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Seven differentially expressed gene (DEG) signatures related to risk score predict overall survival in the patients. A, DEG risk score distribution in each patient. B, Survival days of patients in order of the value of risk scores. C, A heatmap of seven selected genes’ expression profile</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="CAM4-9-1242-g002"></graphic>
</fig>
<fig fig-type="Figure" id="cam42692-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Kaplan‐Meier survival analysis for the patients with high‐grade serous ovarian cancer (HGSOC) in The Cancer Genome Atlas (TCGA) dataset. A, The Kaplan‐Meier curve for patients with HGSOC divided into high‐risk and low‐risk. B, Receiver operating characteristic curve in discriminating patients with high‐risk score from those with low‐risk score (AUC = 0.71)</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="CAM4-9-1242-g003"></graphic>
</fig>
<p>Moreover the prognostic role of the novel risk score was also evaluated together with the classical clinical pathological parameters that might influence the prognosis of HGSOC. Univariate and multivariate Cox regression analysis indicated that only no‐meeting‐objective response (HR = 2.623, <italic>P</italic> &lt; .001) and high‐risk score (HR = 1.899, <italic>P</italic> &lt; .001) were independent prognostic indicators for OS (Table <xref ref-type="table" rid="cam42692-tbl-0004">4</xref>).</p>
<table-wrap id="cam42692-tbl-0004" orientation="portrait" position="float" xml:lang="en">
<label>Table 4</label>
<caption>
<p>Univariate and multivariate analysis for each clinical feature</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="bottom">Pathological parameters</th>
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Univariate Cox regression</th>
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Multivariate Cox regression</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>β</italic> (Cox)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>P</italic>
</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">HR (95% CI)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>β</italic> (Cox)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">
<italic>P</italic>
</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Age (&gt;58/≤58)</p>
<p>163/170</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.037</td>
<td align="char" char="." colspan="1" rowspan="1">.809</td>
<td align="char" char="(" colspan="1" rowspan="1">1.038 (0.768‐1.403)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Grade (G3 ~ 4/G2)</p>
<p>294/39</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.351</td>
<td align="char" char="." colspan="1" rowspan="1">.127</td>
<td align="char" char="(" colspan="1" rowspan="1">1.421 (0.905‐2.229)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Histological stage (III ~ IV/II)</p>
<p>311/21</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.848</td>
<td align="char" char="." colspan="1" rowspan="1">.062</td>
<td align="char" char="(" colspan="1" rowspan="1">2.336 (0.958‐5.695)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Residual tumor (&gt;10/≤10 mm)</p>
<p>84/219</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.225</td>
<td align="char" char="." colspan="1" rowspan="1">.185</td>
<td align="char" char="(" colspan="1" rowspan="1">1.253 (0.898‐1.749)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Anatomic neoplasm subdivision (bilateral/unilateral)</p>
<p>230/87</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.320</td>
<td align="char" char="." colspan="1" rowspan="1">.081</td>
<td align="char" char="(" colspan="1" rowspan="1">1.377 (0.962‐1.972)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Objective response (no/yes)</p>
<p>46/197</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.970</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="char" char="(" colspan="1" rowspan="1">2.639 (1.744‐3.994)</td>
<td align="char" char="." colspan="1" rowspan="1">0.964</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="char" char="(" colspan="1" rowspan="1">2.623 (1.732‐3.971)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Venous invasion (yes/no)</p>
<p>58/38</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">−0.244</td>
<td align="char" char="." colspan="1" rowspan="1">.471</td>
<td align="char" char="(" colspan="1" rowspan="1">0.784 (0.404‐1.520)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Lymphatic invasion (yes/no)</p>
<p>91/45</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.350</td>
<td align="char" char="." colspan="1" rowspan="1">.220</td>
<td align="char" char="(" colspan="1" rowspan="1">1.419 (0.811‐2.482)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Risk score (high/low)</p>
<p>166/167</p>
</td>
<td align="char" char="." colspan="1" rowspan="1">0.733</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="char" char="(" colspan="1" rowspan="1">2.082 (1.530‐2.834)</td>
<td align="char" char="." colspan="1" rowspan="1">0.641</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="char" char="(" colspan="1" rowspan="1">1.899 (1.359‐2.653)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="cam42692-sec-0011">
<label>3.4</label>
<title>Prognosis effect assessment of risk score in subsets of HGSOC patients</title>
<p>Last but not the least, the prognostic value of the risk score in the OS of HGSOC patients was also evaluated in subsets of HGSOC patients with different clinical characteristics, and the results obtained from the analysis are shown in Table <xref ref-type="table" rid="cam42692-tbl-0005">5</xref>. We analyzed the correlation between risk score and OS in different subgroups, such as age (≤58 or &gt;58), histologic grade (high or low differentiation), clinical stage (early or advanced stage), lymphatic invasion, venous invasion, treatment outcome objective response ([OR] or no‐meeting‐objective response), residual tumor size, and anatomic neoplasm subdivision (unilateral or bilateral). Subgroup analyses demonstrated that high‐risk score was associated with poor prognostic in the patients with grade 3‐4 (<italic>P</italic> &lt; .001, Figure <xref ref-type="fig" rid="cam42692-fig-0004">4</xref>A), advanced stage (<italic>P</italic> &lt; .001, Figure <xref ref-type="fig" rid="cam42692-fig-0004">4</xref>B), venous invasion (<italic>P</italic> = .0439, Figure <xref ref-type="fig" rid="cam42692-fig-0004">4</xref>C), and OR subsets (<italic>P</italic> &lt; .001, Figure <xref ref-type="fig" rid="cam42692-fig-0004">4</xref>D) closely. In addition, there were strong relationships between the high‐risk score and low survival rate in different age groups (Figure <xref ref-type="fig" rid="cam42692-fig-0005">5</xref>A), lymphatic invasion (Figure <xref ref-type="fig" rid="cam42692-fig-0005">5</xref>B), residual tumor size (Figure <xref ref-type="fig" rid="cam42692-fig-0005">5</xref>C), anatomic neoplasm subdivision (Figure <xref ref-type="fig" rid="cam42692-fig-0005">5</xref>D). But no significant differences were found between the subgroups in these features.</p>
<table-wrap id="cam42692-tbl-0005" orientation="portrait" position="float" xml:lang="en">
<label>Table 5</label>
<caption>
<p>Correlation of risk scores with overall survival (OS) in subsets of different clinical features</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">3‐y OS rate % (95% CI)</th>
<th align="left" colspan="1" rowspan="1" valign="top">High risk</th>
<th align="left" colspan="1" rowspan="1" valign="top">Low risk</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<italic>P‐</italic>value</th>
<th align="left" colspan="1" rowspan="1" valign="top">Number (high/low)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Age ≤58</td>
<td align="char" char="(" colspan="1" rowspan="1">63.0 (52.0‐76.1)</td>
<td align="left" colspan="1" rowspan="1">85.5 (76.5‐95.5)</td>
<td align="char" char="." colspan="1" rowspan="1">.013</td>
<td align="left" colspan="1" rowspan="1">87/83</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Age &gt;58</td>
<td align="char" char="(" colspan="1" rowspan="1">44.6 (33.6‐59.2)</td>
<td align="left" colspan="1" rowspan="1">71.8 (61.4‐83.9)</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="left" colspan="1" rowspan="1">79/84</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grade 2</td>
<td align="char" char="(" colspan="1" rowspan="1">62.3 (40.9‐94.9)</td>
<td align="left" colspan="1" rowspan="1">88.5 (74.8‐100.0)</td>
<td align="char" char="." colspan="1" rowspan="1">.208</td>
<td align="left" colspan="1" rowspan="1">16/23</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grade 3‐4</td>
<td align="char" char="(" colspan="1" rowspan="1">52.9 (44.3‐63.2)</td>
<td align="left" colspan="1" rowspan="1">76.1 (68.1‐85.1)</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="left" colspan="1" rowspan="1">150/144</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage II</td>
<td align="char" char="(" colspan="1" rowspan="1">50.0 (18.8‐100.0)</td>
<td align="left" colspan="1" rowspan="1">—</td>
<td align="char" char="." colspan="1" rowspan="1">.216</td>
<td align="left" colspan="1" rowspan="1">6/15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage III ~ IV</td>
<td align="char" char="(" colspan="1" rowspan="1">54.6 (46.2‐64.4)</td>
<td align="left" colspan="1" rowspan="1">75.9 (68.1‐84.5)</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="left" colspan="1" rowspan="1">159/152</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Residual tumor ≤10 mm</td>
<td align="char" char="(" colspan="1" rowspan="1">57.6 (47.6‐69.7)</td>
<td align="left" colspan="1" rowspan="1">78.2 (69.2‐88.4)</td>
<td align="char" char="." colspan="1" rowspan="1">.005</td>
<td align="left" colspan="1" rowspan="1">113/106</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Residual tumor &gt;10 mm</td>
<td align="char" char="(" colspan="1" rowspan="1">46.6 (33.0‐65.8)</td>
<td align="left" colspan="1" rowspan="1">68.3 (52.6‐88.6)</td>
<td align="char" char="." colspan="1" rowspan="1">.018</td>
<td align="left" colspan="1" rowspan="1">42/42</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Anatomic neoplasm subdivision (unilateral)</td>
<td align="char" char="(" colspan="1" rowspan="1">48.2 (33.7‐69.0)</td>
<td align="left" colspan="1" rowspan="1">90.2 (80.1‐100.0)</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;.001</td>
<td align="left" colspan="1" rowspan="1">41/46</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Anatomic neoplasm subdivision (Bilateral)</td>
<td align="char" char="(" colspan="1" rowspan="1">58.2 (48.7‐69.5)</td>
<td align="left" colspan="1" rowspan="1">73.1 (63.8‐83.9)</td>
<td align="char" char="." colspan="1" rowspan="1">.013</td>
<td align="left" colspan="1" rowspan="1">119/111</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Objective response: yes</td>
<td align="char" char="(" colspan="1" rowspan="1">62.1 (52.3‐73.9)</td>
<td align="left" colspan="1" rowspan="1">80.8 (72.5‐90.1)</td>
<td align="char" char="." colspan="1" rowspan="1">.001</td>
<td align="left" colspan="1" rowspan="1">93/104</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Objective response: no</td>
<td align="char" char="(" colspan="1" rowspan="1">24.6 (10.9‐55.5)</td>
<td align="left" colspan="1" rowspan="1">51.1 (28.7‐90.8)</td>
<td align="char" char="." colspan="1" rowspan="1">.070</td>
<td align="left" colspan="1" rowspan="1">25/21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lymphatic invasion: no</td>
<td align="char" char="(" colspan="1" rowspan="1">58.4 (37.4‐91.3)</td>
<td align="left" colspan="1" rowspan="1">93.3 (81.5‐100.0)</td>
<td align="char" char="." colspan="1" rowspan="1">.015</td>
<td align="left" colspan="1" rowspan="1">22/23</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lymphatic invasion: yes</td>
<td align="char" char="(" colspan="1" rowspan="1">49.0 (34.3‐70.0)</td>
<td align="left" colspan="1" rowspan="1">74.0 (59.7‐91.8)</td>
<td align="char" char="." colspan="1" rowspan="1">.002</td>
<td align="left" colspan="1" rowspan="1">46/45</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Venous invasion: no</td>
<td align="char" char="(" colspan="1" rowspan="1">48.4 (26.3‐88.8)</td>
<td align="left" colspan="1" rowspan="1">85.7 (69.2‐100.0)</td>
<td align="char" char="." colspan="1" rowspan="1">.060</td>
<td align="left" colspan="1" rowspan="1">17/21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Venous invasion: yes</td>
<td align="char" char="(" colspan="1" rowspan="1">59.9 (41.3‐86.8)</td>
<td align="left" colspan="1" rowspan="1">83.3 (69.2‐100.0)</td>
<td align="char" char="." colspan="1" rowspan="1">.044</td>
<td align="left" colspan="1" rowspan="1">26/32</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<fig fig-type="Figure" id="cam42692-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>Kaplan‐Meier curves for prognostic value of risk‐score signature for patients divided by each clinical feature. A, Grade. B, Stage. C, Venous invasion. D, Objective response</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="CAM4-9-1242-g004"></graphic>
</fig>
<fig fig-type="Figure" id="cam42692-fig-0005" orientation="portrait" position="float" xml:lang="en">
<label>Figure 5</label>
<caption>
<p>Kaplan‐Meier curves for prognostic value of risk‐score signature for patients divided by each clinical feature. A, Age. B, Lymphatic invasion. C, Residual tumor size. D, Anatomic neoplasm subdivision</p>
</caption>
<graphic id="nlm-graphic-11" xlink:href="CAM4-9-1242-g005"></graphic>
</fig>
</sec>
</sec>
<sec id="cam42692-sec-0012" sec-type="discussion">
<label>4</label>
<title>DISCUSSION</title>
<p>High‐grade serous ovarian cancer is the main histological type that causes death in patients with ovarian cancer. Therefore, studying signatures with prognostic value would be critical for treatment improvement of HGSOC patients. In this study, a potential platinum resistant‐related risk signature was built and evaluated to predict survival in HGSOC according to the results of DEGs identification involved in platinum‐resistant and Cox proportional regression analysis. The risk score computed according to coefficients and expressions of seven mRNAs, including LRRC17, ZHX3, CD38, AKR1B10, LYPD6B, KIAA2022, and CMBL, could serve as an accurate and independent prognostic indicator for HGSOC. Several single genes were shown to be a powerful in assessment of prognosis for HGSOC. For example, some studies focused their point on the prognostic value of apolipoprotein B mRNA editing enzyme catalytic subunit 3 (APOBEC3) and folate receptor 1 (FOLR1).<xref ref-type="ref" rid="cam42692-bib-0027">27</xref>, <xref ref-type="ref" rid="cam42692-bib-0028">28</xref> Similarly, a study highlighted the prognostic value of a 11‐gene model which was obtained by Rebust likelihood‐based study on ovarian samples from TCGA.<xref ref-type="ref" rid="cam42692-bib-0029">29</xref> Despite those surprising findings, no biomarkers for prognosis prediction of HGSOC were yet in clinical use. However, there was no large scale genomic analysis studied the collaborative effect of multiple genes related to platinum resistance on the prognosis in HGSOC. Therefore, it is extremely important to find and design a new model that can predict the prognosis of platinum resistance in HGSOC and with which we can predict the prognosis of patients with HGSOC and take corresponding treatment measures.</p>
<p>Platinum‐based chemotherapy combined with debulking surgery is the standard therapy for ovarian cancer patients. Despite high response rate to initial therapy, many patients would suffer platinum resistance and relapse after that, which lead to poor prognosis. So, we attempt to construct a potential platinum‐resistant focused model to predict the OS in HGSOC patients. Firstly, a total of 269 DEGs between platinum‐resistant and sensitive HGSOC tissue samples were obtained. To understand the functions of DEGs, gene function analysis was performed. DEGs were involved in many biological processes related to drug resistance, such as signal transduction and apoptosis process. They may also participate in the drug resistance of ovarian cancer through PI3K‐Akt signaling pathway and drug metabolism—cytochrome P450. Next, a prognosis model consisted of seven DEGs (LRRC17, ZHX3, CD38, AKR1B10, LYPD6B, KIAA2022, and CMBL) was constructed based on relationships between DEGs and the OS in 333 HGSOC patients from TCGA. Among them, LYPD6B, CD38, CMBL, and KIAA2022 were regarded as independent protective factors, while others were defined as risky factors. Surprisingly, survival and ROC curve analyses revealed that the risk score generated from the prognosis model could serve as an indicator of the OS in HGSOC with certain accuracy. Moreover the independence of prognosis effect was also confirmed through comparing the novel risk score with classical clinical pathological parameters.</p>
<p>Among the identified seven genes (LRRC17, ZHX3, CD38, AKR1B10, LYPD6B, KIAA2022, and CMBL) in our study, CD38 was well known about its correlation with hematological malignancies. High expression of CD38 was associated with shorter lymphocyte doubling time and poor prognosis in chronic lymphocytic leukemia<xref ref-type="ref" rid="cam42692-bib-0030">30</xref> In addition, several studied argued that CD38 played vital role in multiple myeloma.<xref ref-type="ref" rid="cam42692-bib-0031">31</xref>, <xref ref-type="ref" rid="cam42692-bib-0032">32</xref>, <xref ref-type="ref" rid="cam42692-bib-0033">33</xref> AKR1B10 is a member of aldo‐keto reductase family 1 member B subfamily and expressed in normal epithelial cells of the digestive tract as a cytosolic reductase.<xref ref-type="ref" rid="cam42692-bib-0034">34</xref> It has been observed that AKR1B10 was associated with survival in gastric cancer, colorectal cancer, and hepatocellular carcinoma.<xref ref-type="ref" rid="cam42692-bib-0035">35</xref>, <xref ref-type="ref" rid="cam42692-bib-0036">36</xref>, <xref ref-type="ref" rid="cam42692-bib-0037">37</xref> To date, Very little is currently known about AKR1B10 in ovarian cancer. Hong et al found that the low expression of LRRC17 was a risk factor for fracture in postmenopausal women.<xref ref-type="ref" rid="cam42692-bib-0038">38</xref> However, there is little published data on LRRC17 function in cancer.<xref ref-type="ref" rid="cam42692-bib-0039">39</xref>, <xref ref-type="ref" rid="cam42692-bib-0040">40</xref> Ochoa et al<xref ref-type="ref" rid="cam42692-bib-0041">41</xref>, <xref ref-type="ref" rid="cam42692-bib-0042">42</xref> suggested that LYPD6B enhanced the sensitivity of (α3)3(β4)2 nicotinic acetylcholine (ACh) receptors to ACh. CMBL, which is a highly expressed in liver cytosol, was the primary cysteine hydrolase to bioactivate Olmesartan Medoxomil in the liver and intestine.<xref ref-type="ref" rid="cam42692-bib-0043">43</xref>, <xref ref-type="ref" rid="cam42692-bib-0044">44</xref> Existing research has recognized the critical role of KIAA2022 in X‐linked mental retardation (XLMR) and brain development.<xref ref-type="ref" rid="cam42692-bib-0045">45</xref>, <xref ref-type="ref" rid="cam42692-bib-0046">46</xref>, <xref ref-type="ref" rid="cam42692-bib-0047">47</xref>, <xref ref-type="ref" rid="cam42692-bib-0048">48</xref>, <xref ref-type="ref" rid="cam42692-bib-0049">49</xref> KIAA2022 enhanced cell adhesion and migration by regulating adhesion molecules expression, such as N‐Cadherin and β1‐integrin.<xref ref-type="ref" rid="cam42692-bib-0047">47</xref>, <xref ref-type="ref" rid="cam42692-bib-0050">50</xref> ZHX3 is a member of the zinc fingers and homeoboxes (ZHX) gene family. Although it is now well established that ZHX1 and ZHX2 worked as tumor suppressors,<xref ref-type="ref" rid="cam42692-bib-0051">51</xref>, <xref ref-type="ref" rid="cam42692-bib-0052">52</xref>, <xref ref-type="ref" rid="cam42692-bib-0053">53</xref> the role of ZHX3 in cancer is not clear. Studies showed that ZHX3 was upregulated and might be an independent indicator of the OS in renal clear cell carcinoma.<xref ref-type="ref" rid="cam42692-bib-0054">54</xref>, <xref ref-type="ref" rid="cam42692-bib-0055">55</xref>
</p>
<p>In the final part of this study, the prognosis efficacy of risk score was also evaluated in subsets of HGSOC patients with different clinical characteristics. Subgroup analyses demonstrated that high‐risk score was associated with shorter OS closely in the Grade 3‐4, late stage, venous invasion, and OR subsets. There also were strong relationships between the high‐risk score and low survival rate no matter what the age, lymphatic invasion, residual tumor size, anatomic neoplasm subdivision are. These findings, while preliminary, have important implications for developing platinum‐resistant focused indicator for survival assessment in HGSOC. The risk score will provide a new direction for the evaluation of HGSOC prognosis, which is different from the traditional assessment system. It might be helpful for individualized treatment and survival improvement through further patient stratification.</p>
<p>Additionally, some limitations of this study should be considered. First, the sample size in this study is small, so further validations with larger samples and other experimental methods are quite essential. Second, this study was limited to the analysis of mRNA expression profile without considering interactions with miRNA, lncRNA, and other factors, further comprehensive study are expected to be done. Third, previous studies of LRRC17, ZHX3, LYPD6B, KIAA2022, and CMBL in cancer still remain paucity despite the importance of them. Extensive researches are required to answer this question.</p>
<p>In conclusion, to the best of our knowledge, we have identified seven genes associated with platinum resistance in HGSOC patients using the Cox regression model. Further analysis revealed that the seven‐gene signature could be an independent factor predicting the prognosis of the platinum resistance in HGSOC patients. These findings may be a potential biomarker for the prognosis of platinum resistance and provide insights into theoretical guidance and decision making in clinical practice of HGSOC.</p>
</sec>
<sec id="cam42692-sec-0013" sec-type="COI-statement">
<title>CONFLICT OF INTEREST</title>
<p>None declared.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="cam42692-sup-0001">
<caption>
<p> </p>
</caption>
<media xlink:href="CAM4-9-1242-s001.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="cam42692-sup-0002">
<caption>
<p> </p>
</caption>
<media xlink:href="CAM4-9-1242-s002.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="cam42692-sup-0003">
<caption>
<p> </p>
</caption>
<media xlink:href="CAM4-9-1242-s003.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="cam42692-sup-0004">
<caption>
<p> </p>
</caption>
<media xlink:href="CAM4-9-1242-s004.doc">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="cam42692-sec-0014">
<title>ACKNOWLEDGEMENTS</title>
<p>We thank Prof. Yuzong Chen (Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore) for valuable suggestions on the paper.</p>
</ack>
<ref-list content-type="cited-references" id="cam42692-bibl-0001">
<title>REFERENCES</title>
<ref id="cam42692-bib-0001">
<label>1</label>
<mixed-citation id="cam42692-cit-0001" publication-type="journal">
<string-name>
<surname>Torre</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Trabert</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>DeSantis</surname>
<given-names>CE</given-names>
</string-name>, et al. <article-title>Ovarian cancer statistics, 2018</article-title>. <source xml:lang="en"/>CA Cancer J Clin. <year>2018</year>;<volume>68</volume>(<issue>4</issue>):<fpage>284</fpage>‐<lpage>296</lpage>.<pub-id pub-id-type="pmid">29809280</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0002">
<label>2</label>
<mixed-citation id="cam42692-cit-0002" publication-type="journal">
<string-name>
<surname>Romero</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bast</surname>
<given-names>RC</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy</article-title>. <source xml:lang="en"/>Endocrinology. <year>2012</year>;<volume>153</volume>:<fpage>1593</fpage>‐<lpage>1602</lpage>.<pub-id pub-id-type="pmid">22416079</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0003">
<label>3</label>
<mixed-citation id="cam42692-cit-0003" publication-type="journal">
<string-name>
<surname>McPherson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Roth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Laks</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Divergent modes of clonal spread and intraperitoneal mixing in high‐grade serous ovarian cancer</article-title>. <source xml:lang="en"/>Nat Genet. <year>2016</year>;<volume>48</volume>:<fpage>758</fpage>‐<lpage>767</lpage>.<pub-id pub-id-type="pmid">27182968</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0004">
<label>4</label>
<mixed-citation id="cam42692-cit-0004" publication-type="journal">
<string-name>
<surname>Yin</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Lloyd</surname>
<given-names>KO</given-names>
</string-name>. <article-title>Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16</article-title>. <source xml:lang="en"/>J Biol Chem. <year>2001</year>;<volume>276</volume>:<fpage>27371</fpage>‐<lpage>27375</lpage>.<pub-id pub-id-type="pmid">11369781</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0005">
<label>5</label>
<mixed-citation id="cam42692-cit-0005" publication-type="journal">
<string-name>
<surname>Makar</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Kristensen</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Kaern</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bormer</surname>
<given-names>OP</given-names>
</string-name>, <string-name>
<surname>Abeler</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Trope</surname>
<given-names>CG</given-names>
</string-name>. <article-title>Prognostic value of pre‐ and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis</article-title>. <source xml:lang="en"/>Obstet Gynecol. <year>1992</year>;<volume>79</volume>:<fpage>1002</fpage>‐<lpage>1010</lpage>.<pub-id pub-id-type="pmid">1579296</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0006">
<label>6</label>
<mixed-citation id="cam42692-cit-0006" publication-type="journal">
<string-name>
<surname>Scholl</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Bascou</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Mosseri</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Circulating levels of colony‐stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer</article-title>. <source xml:lang="en"/>Br J Cancer. <year>1994</year>;<volume>69</volume>:<fpage>342</fpage>‐<lpage>346</lpage>.<pub-id pub-id-type="pmid">8297732</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0007">
<label>7</label>
<mixed-citation id="cam42692-cit-0007" publication-type="journal">
<string-name>
<surname>Venesmaa</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lehtovirta</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stenman</surname>
<given-names>UH</given-names>
</string-name>, <string-name>
<surname>Leminen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Forss</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ylikorkala</surname>
<given-names>O</given-names>
</string-name>. <article-title>Tumour‐associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer</article-title>. <source xml:lang="en"/>Br J Cancer. <year>1994</year>;<volume>70</volume>:<fpage>1188</fpage>‐<lpage>1190</lpage>.<pub-id pub-id-type="pmid">7981075</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0008">
<label>8</label>
<mixed-citation id="cam42692-cit-0008" publication-type="journal">
<string-name>
<surname>Mankoo</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Levine</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Sander</surname>
<given-names>C</given-names>
</string-name>. <article-title>Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2011</year>;<volume>6</volume>:<elocation-id>e24709</elocation-id>.<pub-id pub-id-type="pmid">22073136</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0009">
<label>9</label>
<mixed-citation id="cam42692-cit-0009" publication-type="journal">
<string-name>
<surname>Miller</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high‐grade serous ovarian cancer following primary cytoreductive surgery and first‐line adjuvant chemotherapy</article-title>. <source xml:lang="en"/>Gynecol Oncol. <year>2018</year>;<volume>149</volume>:<fpage>155</fpage>‐<lpage>162</lpage>.<pub-id pub-id-type="pmid">29402501</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0010">
<label>10</label>
<mixed-citation id="cam42692-cit-0010" publication-type="journal">
<string-name>
<surname>Bonome</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Levine</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Shih</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer</article-title>. <source xml:lang="en"/>Can Res. <year>2008</year>;<volume>68</volume>:<fpage>5478</fpage>‐<lpage>5486</lpage>.</mixed-citation>
</ref>
<ref id="cam42692-bib-0011">
<label>11</label>
<mixed-citation id="cam42692-cit-0011" publication-type="journal">
<string-name>
<surname>Cheon</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Tong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sim</surname>
<given-names>MS</given-names>
</string-name>, et al. <article-title>A collagen‐remodeling gene signature regulated by TGF‐beta signaling is associated with metastasis and poor survival in serous ovarian cancer</article-title>. <source xml:lang="en"/>Clin Cancer Res. <year>2014</year>;<volume>20</volume>:<fpage>711</fpage>‐<lpage>723</lpage>.<pub-id pub-id-type="pmid">24218511</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0012">
<label>12</label>
<mixed-citation id="cam42692-cit-0012" publication-type="journal">
<string-name>
<surname>Crijns</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Fehrmann</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>de Jong</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Survival‐related profile, pathways, and transcription factors in ovarian cancer</article-title>. <source xml:lang="en"/>PLoS Med. <year>2009</year>;<volume>6</volume>:<fpage>e24</fpage>.<pub-id pub-id-type="pmid">19192944</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0013">
<label>13</label>
<mixed-citation id="cam42692-cit-0013" publication-type="journal">
<string-name>
<surname>Edgar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Domrachev</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lash</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Gene expression omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source xml:lang="en"/>Nucleic Acids Res. <year>2002</year>;<volume>30</volume>:<fpage>207</fpage>‐<lpage>210</lpage>.<pub-id pub-id-type="pmid">11752295</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0014">
<label>14</label>
<mixed-citation id="cam42692-cit-0014" publication-type="journal">
<string-name>
<surname>Hudson</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Artez</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>International network of cancer genome projects</article-title>. <source xml:lang="en"/>Nature. <year>2010</year>;<volume>464</volume>:<fpage>993</fpage>‐<lpage>998</lpage>.<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0015">
<label>15</label>
<mixed-citation id="cam42692-cit-0015" publication-type="journal">
<string-name>
<surname>Koti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gooding</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Nuin</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Identification of the IGF1/PI3K/NF kappaB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high‐grade serous epithelial ovarian cancer</article-title>. <source xml:lang="en"/>BMC Cancer. <year>2013</year>;<volume>13</volume>:<fpage>549</fpage>.<pub-id pub-id-type="pmid">24237932</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0016">
<label>16</label>
<mixed-citation id="cam42692-cit-0016" publication-type="journal">
<string-name>
<surname>Yoshihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tsunoda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shigemizu</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>High‐risk ovarian cancer based on 126‐gene expression signature is uniquely characterized by downregulation of antigen presentation pathway</article-title>. <source xml:lang="en"/>Clin Cancer Res. <year>2012</year>;<volume>18</volume>:<fpage>1374</fpage>‐<lpage>1385</lpage>.<pub-id pub-id-type="pmid">22241791</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0017">
<label>17</label>
<mixed-citation id="cam42692-cit-0017" publication-type="journal">
<string-name>
<surname>Uehara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Correction: integrated copy number and expression analysis identifies profiles of whole‐arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2015</year>;<volume>10</volume>:<elocation-id>e0132751</elocation-id>.<pub-id pub-id-type="pmid">26147301</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0018">
<label>18</label>
<mixed-citation id="cam42692-cit-0018" publication-type="journal">
<string-name>
<surname>Mateescu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Batista</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cardon</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>miR‐141 and miR‐200a act on ovarian tumorigenesis by controlling oxidative stress response</article-title>. <source xml:lang="en"/>Nat Med. <year>2011</year>;<volume>17</volume>:<fpage>1627</fpage>‐<lpage>1635</lpage>.<pub-id pub-id-type="pmid">22101765</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0019">
<label>19</label>
<mixed-citation id="cam42692-cit-0019" publication-type="journal">
<string-name>
<surname>Ritchie</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Phipson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>limma powers differential expression analyses for RNA‐sequencing and microarray studies</article-title>. <source xml:lang="en"/>Nucleic Acids Res. <year>2015</year>;<volume>43</volume>:<fpage>e47</fpage>.<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0020">
<label>20</label>
<mixed-citation id="cam42692-cit-0020" publication-type="journal">
<string-name>
<surname>Troyanskaya</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Cantor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sherlock</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Missing value estimation methods for DNA microarrays</article-title>. <source xml:lang="en"/>Bioinformatics (Oxford, England). <year>2001</year>;<volume>17</volume>:<fpage>520</fpage>‐<lpage>525</lpage>.</mixed-citation>
</ref>
<ref id="cam42692-bib-0021">
<label>21</label>
<mixed-citation id="cam42692-cit-0021" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Grennan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Badner</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2011</year>;<volume>6</volume>:<fpage>e17238</fpage>.<pub-id pub-id-type="pmid">21386892</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0022">
<label>22</label>
<mixed-citation id="cam42692-cit-0022" publication-type="journal">
<string-name>
<surname>Huang da</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Lempicki</surname>
<given-names>RA</given-names>
</string-name>
<article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source xml:lang="en"/>Nat Protoc. <year>2009</year>;<volume>4</volume>:<fpage>44</fpage>‐<lpage>57</lpage>.<pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0023">
<label>23</label>
<mixed-citation id="cam42692-cit-0023" publication-type="journal">
<string-name>
<surname>Kanehisa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Furumichi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tanabe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Morishima</surname>
<given-names>K</given-names>
</string-name>. <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source xml:lang="en"/>Nucleic Acids Res. <year>2017</year>;<volume>45</volume>:<fpage>D353</fpage>‐<lpage>D361</lpage>.<pub-id pub-id-type="pmid">27899662</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0024">
<label>24</label>
<mixed-citation id="cam42692-cit-0024" publication-type="journal">
<string-name>
<surname>Moreno‐Betancur</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sadaoui</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Piffaretti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rey</surname>
<given-names>G</given-names>
</string-name>. <article-title>Survival analysis with multiple causes of death: extending the competing risks model</article-title>. <source xml:lang="en"/>Epidemiology (Cambridge, Mass.). <year>2017</year>;<volume>28</volume>:<fpage>12</fpage>‐<lpage>19</lpage>.</mixed-citation>
</ref>
<ref id="cam42692-bib-0025">
<label>25</label>
<mixed-citation id="cam42692-cit-0025" publication-type="journal">
<string-name>
<surname>Zeng</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>RQ</given-names>
</string-name>, et al. <article-title>Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma</article-title>. <source xml:lang="en"/>Oncotarget. <year>2017</year>;<volume>8</volume>:<fpage>16811</fpage>‐<lpage>16828</lpage>.<pub-id pub-id-type="pmid">28187432</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0026">
<label>26</label>
<mixed-citation id="cam42692-cit-0026" publication-type="journal">
<string-name>
<surname>Heagerty</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Survival model predictive accuracy and ROC curves</article-title>. <source xml:lang="en"/>Biometrics. <year>2005</year>;<volume>61</volume>:<fpage>92</fpage>‐<lpage>105</lpage>.<pub-id pub-id-type="pmid">15737082</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0027">
<label>27</label>
<mixed-citation id="cam42692-cit-0027" publication-type="journal">
<string-name>
<surname>Leonard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Starrett</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Maurer</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>APOBEC3G expression correlates with T‐cell infiltration and improved clinical outcomes in high‐grade serous ovarian carcinoma</article-title>. <source xml:lang="en"/>Clin Cancer Res. <year>2016</year>;<volume>22</volume>:<fpage>4746</fpage>‐<lpage>4755</lpage>.<pub-id pub-id-type="pmid">27016308</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0028">
<label>28</label>
<mixed-citation id="cam42692-cit-0028" publication-type="journal">
<string-name>
<surname>Kobel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Madore</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ramus</surname>
<given-names>SJ</given-names>
</string-name>, et al. <article-title>Evidence for a time‐dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study</article-title>. <source xml:lang="en"/>Br J Cancer. <year>2014</year>;<volume>111</volume>:<fpage>2297</fpage>‐<lpage>2307</lpage>.<pub-id pub-id-type="pmid">25349970</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0029">
<label>29</label>
<mixed-citation id="cam42692-cit-0029" publication-type="journal">
<string-name>
<surname>Men</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>QN</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>Q</given-names>
</string-name>. <article-title>A prognostic 11 genes expression model for ovarian cancer</article-title>. <source xml:lang="en"/>J Cell Biochem. <year>2018</year>;<volume>119</volume>:<fpage>1971</fpage>‐<lpage>1978</lpage>.<pub-id pub-id-type="pmid">28817186</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0030">
<label>30</label>
<mixed-citation id="cam42692-cit-0030" publication-type="journal">
<string-name>
<surname>Malavasi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Deaglio</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Damle</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cutrona</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ferrarini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chiorazzi</surname>
<given-names>N</given-names>
</string-name>. <article-title>CD38 and chronic lymphocytic leukemia: a decade later</article-title>. <source xml:lang="en"/>Blood. <year>2011</year>;<volume>118</volume>:<fpage>3470</fpage>‐<lpage>3478</lpage>.<pub-id pub-id-type="pmid">21765022</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0031">
<label>31</label>
<mixed-citation id="cam42692-cit-0031" publication-type="journal">
<string-name>
<surname>Gao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Camacho</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Mehta</surname>
<given-names>K</given-names>
</string-name>. <article-title>Retinoic acid‐induced CD38 antigen promotes leukemia cells attachment and interferon‐gamma/interleukin‐1beta‐dependent apoptosis of endothelial cells: implications in the etiology of retinoic acid syndrome</article-title>. <source xml:lang="en"/>Leuk Res. <year>2007</year>;<volume>31</volume>:<fpage>455</fpage>‐<lpage>463</lpage>.<pub-id pub-id-type="pmid">16920192</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0032">
<label>32</label>
<mixed-citation id="cam42692-cit-0032" publication-type="journal">
<string-name>
<surname>Colaianni</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Di Benedetto</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton</article-title>. <source xml:lang="en"/>J Biol Chem. <year>2012</year>;<volume>287</volume>:<fpage>29159</fpage>‐<lpage>29167</lpage>.<pub-id pub-id-type="pmid">22761429</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0033">
<label>33</label>
<mixed-citation id="cam42692-cit-0033" publication-type="journal">
<string-name>
<surname>Colaianni</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Di Benedetto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>LL</given-names>
</string-name>, et al. <article-title>Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts</article-title>. <source xml:lang="en"/>Biochem Biophys Res Comm. <year>2011</year>;<volume>411</volume>:<fpage>512</fpage>‐<lpage>515</lpage>.<pub-id pub-id-type="pmid">21741363</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0034">
<label>34</label>
<mixed-citation id="cam42692-cit-0034" publication-type="journal">
<string-name>
<surname>Hyndman</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Flynn</surname>
<given-names>TG</given-names>
</string-name>. <article-title>Sequence and expression levels in human tissues of a new member of the aldo‐keto reductase family</article-title>. <source xml:lang="en"/>Biochem Biophys Acta. <year>1998</year>;<volume>1399</volume>:<fpage>198</fpage>‐<lpage>202</lpage>.<pub-id pub-id-type="pmid">9765596</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0035">
<label>35</label>
<mixed-citation id="cam42692-cit-0035" publication-type="journal">
<string-name>
<surname>Ohashi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Idogawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tokino</surname>
<given-names>T</given-names>
</string-name>. <article-title>AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis</article-title>. <source xml:lang="en"/>Mol Cancer Res. <year>2013</year>;<volume>11</volume>:<fpage>1554</fpage>‐<lpage>1563</lpage>.<pub-id pub-id-type="pmid">24140838</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0036">
<label>36</label>
<mixed-citation id="cam42692-cit-0036" publication-type="journal">
<string-name>
<surname>Yao</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>LG</given-names>
</string-name>, et al. <article-title>AKR1B10, a good prognostic indicator in gastric cancer</article-title>. <source xml:lang="en"/>Eur J Surg Oncol. <year>2014</year>;<volume>40</volume>:<fpage>318</fpage>‐<lpage>324</lpage>.<pub-id pub-id-type="pmid">24406159</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0037">
<label>37</label>
<mixed-citation id="cam42692-cit-0037" publication-type="journal">
<string-name>
<surname>Ha</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>CK</given-names>
</string-name>. <article-title>High expression of aldo‐keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma</article-title>. <source xml:lang="en"/>Gut Liv. <year>2014</year>;<volume>8</volume>:<fpage>648</fpage>‐<lpage>654</lpage>.</mixed-citation>
</ref>
<ref id="cam42692-bib-0038">
<label>38</label>
<mixed-citation id="cam42692-cit-0038" publication-type="journal">
<string-name>
<surname>Hong</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>CH</given-names>
</string-name>, et al. <article-title>Low plasma level of leucine‐rich repeat‐containing 17 (LRRc17) is an independent and additive risk factor for osteoporotic fractures in postmenopausal women</article-title>. <source xml:lang="en"/>J Bone Miner Res. <year>2016</year>;<volume>31</volume>:<fpage>2106</fpage>‐<lpage>2114</lpage>.<pub-id pub-id-type="pmid">27355564</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0039">
<label>39</label>
<mixed-citation id="cam42692-cit-0039" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SH</given-names>
</string-name>, et al. <article-title>Identification of LRRc17 as a negative regulator of receptor activator of NF‐kappaB ligand (RANKL)‐induced osteoclast differentiation</article-title>. <source xml:lang="en"/>J Biol Chem. <year>2009</year>;<volume>284</volume>:<fpage>15308</fpage>‐<lpage>15316</lpage>.<pub-id pub-id-type="pmid">19336404</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0040">
<label>40</label>
<mixed-citation id="cam42692-cit-0040" publication-type="journal">
<string-name>
<surname>Hsia</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Ashley</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ouaret</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Wilding</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bodmer</surname>
<given-names>WF</given-names>
</string-name>. <article-title>Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci USA. <year>2016</year>;<volume>113</volume>:<fpage>E2162</fpage>‐<lpage>E2171</lpage>.<pub-id pub-id-type="pmid">27036009</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0041">
<label>41</label>
<mixed-citation id="cam42692-cit-0041" publication-type="journal">
<string-name>
<surname>Ochoa</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Nishi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Whiteaker</surname>
<given-names>P</given-names>
</string-name>. <article-title>The prototoxin LYPD6B modulates heteromeric alpha3beta4‐containing nicotinic acetylcholine receptors, but not alpha7 homomers</article-title>. <source xml:lang="en"/>FASEB J. <year>2016</year>;<volume>30</volume>:<fpage>1109</fpage>‐<lpage>1119</lpage>.<pub-id pub-id-type="pmid">26586467</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0042">
<label>42</label>
<mixed-citation id="cam42692-cit-0042" publication-type="journal">
<string-name>
<surname>Chung</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Mullegama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Marshall</surname>
<given-names>CR</given-names>
</string-name>, et al. <article-title>Severe intellectual disability and autistic features associated with microduplication 2q23.1</article-title>. <source xml:lang="en"/>Eur J Hum Genet. <year>2012</year>;<volume>20</volume>:<fpage>398</fpage>‐<lpage>403</lpage>.<pub-id pub-id-type="pmid">22085900</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0043">
<label>43</label>
<mixed-citation id="cam42692-cit-0043" publication-type="journal">
<string-name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujimori</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine</article-title>. <source xml:lang="en"/>J Biol Chem. <year>2010</year>;<volume>285</volume>:<fpage>11892</fpage>‐<lpage>11902</lpage>.<pub-id pub-id-type="pmid">20177059</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0044">
<label>44</label>
<mixed-citation id="cam42692-cit-0044" publication-type="journal">
<string-name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshigae</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Murayama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Izumi</surname>
<given-names>T</given-names>
</string-name>. <article-title>Different hydrolases involved in bioactivation of prodrug‐type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1</article-title>. <source xml:lang="en"/>Drug Metab Dispos. <year>2013</year>;<volume>41</volume>:<fpage>1888</fpage>‐<lpage>1895</lpage>.<pub-id pub-id-type="pmid">23946449</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0045">
<label>45</label>
<mixed-citation id="cam42692-cit-0045" publication-type="journal">
<string-name>
<surname>Cantagrel</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lossi</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Boulanger</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males</article-title>. <source xml:lang="en"/>J Med Genet. <year>2004</year>;<volume>41</volume>:<fpage>736</fpage>‐<lpage>742</lpage>.<pub-id pub-id-type="pmid">15466006</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0046">
<label>46</label>
<mixed-citation id="cam42692-cit-0046" publication-type="journal">
<string-name>
<surname>de Lange</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Helbig</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Weckhuysen</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>novo mutations of KIAA2022 in females cause intellectual disability and intractable epilepsy</article-title>. <source xml:lang="en"/>J Med Genet. <year>2016</year>;<volume>53</volume>:<fpage>850</fpage>‐<lpage>858</lpage>.<pub-id pub-id-type="pmid">27358180</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0047">
<label>47</label>
<mixed-citation id="cam42692-cit-0047" publication-type="journal">
<string-name>
<surname>Gilbert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Man</surname>
<given-names>HY</given-names>
</string-name>. <article-title>The X‐linked autism protein KIAA2022/KIDLIA regulates neurite outgrowth via N‐cadherin and delta‐catenin signaling</article-title>. <source xml:lang="en"/>eNeuro. <year>2016</year>;<volume>3</volume>:<fpage>1</fpage>‐<lpage>17</lpage>.</mixed-citation>
</ref>
<ref id="cam42692-bib-0048">
<label>48</label>
<mixed-citation id="cam42692-cit-0048" publication-type="journal">
<string-name>
<surname>Kuroda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ohashi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Naruto</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Delineation of the KIAA2022 mutation phenotype: two patients with X‐linked intellectual disability and distinctive features</article-title>. <source xml:lang="en"/>Am J Med Genet A. <year>2015</year>;<volume>167</volume>:<fpage>1349</fpage>‐<lpage>1353</lpage>.<pub-id pub-id-type="pmid">25900396</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0049">
<label>49</label>
<mixed-citation id="cam42692-cit-0049" publication-type="journal">
<string-name>
<surname>Van Maldergem</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hou</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Kalscheuer</surname>
<given-names>VM</given-names>
</string-name>, et al. <article-title>Loss of function of KIAA2022 causes mild to severe intellectual disability with an autism spectrum disorder and impairs neurite outgrowth</article-title>. <source xml:lang="en"/>Hum Mol Genet. <year>2013</year>;<volume>22</volume>:<fpage>3306</fpage>‐<lpage>3314</lpage>.<pub-id pub-id-type="pmid">23615299</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0050">
<label>50</label>
<mixed-citation id="cam42692-cit-0050" publication-type="journal">
<string-name>
<surname>Magome</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hattori</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Taniguchi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>XLMR protein related to neurite extension (Xpn/KIAA2022) regulates cell‐cell and cell‐matrix adhesion and migration</article-title>. <source xml:lang="en"/>Neurochem Int. <year>2013</year>;<volume>63</volume>:<fpage>561</fpage>‐<lpage>569</lpage>.<pub-id pub-id-type="pmid">24071057</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0051">
<label>51</label>
<mixed-citation id="cam42692-cit-0051" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Construction of a recombinant eukaryotic human ZHX1 gene expression plasmid and the role of ZHX1 in hepatocellular carcinoma</article-title>. <source xml:lang="en"/>Mol Med Rep. <year>2013</year>;<volume>8</volume>:<fpage>1531</fpage>‐<lpage>1536</lpage>.<pub-id pub-id-type="pmid">24064680</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0052">
<label>52</label>
<mixed-citation id="cam42692-cit-0052" publication-type="journal">
<string-name>
<surname>Ma</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>. <article-title>ZHX1 inhibits gastric cancer cell growth through inducing cell‐cycle arrest and apoptosis</article-title>. <source xml:lang="en"/>J Cancer. <year>2016</year>;<volume>7</volume>:<fpage>60</fpage>‐<lpage>68</lpage>.<pub-id pub-id-type="pmid">26722361</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0053">
<label>53</label>
<mixed-citation id="cam42692-cit-0053" publication-type="journal">
<string-name>
<surname>Yue</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E</article-title>. <source xml:lang="en"/>Gastroenterology. <year>2012</year>;<volume>142</volume>:<fpage>1559</fpage>‐<lpage>1570.e2</lpage>.<pub-id pub-id-type="pmid">22406477</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0054">
<label>54</label>
<mixed-citation id="cam42692-cit-0054" publication-type="journal">
<string-name>
<surname>Kwon</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>DC</given-names>
</string-name>, et al. <article-title>Expression and prognostic significance of zinc fingers and homeoboxes family members in renal cell carcinoma</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2017</year>;<volume>12</volume>:<elocation-id>e0171036</elocation-id>.<pub-id pub-id-type="pmid">28152006</pub-id></mixed-citation>
</ref>
<ref id="cam42692-bib-0055">
<label>55</label>
<mixed-citation id="cam42692-cit-0055" publication-type="journal">
<string-name>
<surname>Suehiro</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kawamoto</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Impact of zinc fingers and homeoboxes 3 on the regulation of mesenchymal stem cell osteogenic differentiation</article-title>. <source xml:lang="en"/>Stem Cells Dev. <year>2011</year>;<volume>20</volume>:<fpage>1539</fpage>‐<lpage>1547</lpage>.<pub-id pub-id-type="pmid">21174497</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>